Tackling India's Escalating Healthcare Crisis of Overtreatment and Excessive Polypharmacy
Structural commercialization and diagnostic cascades drive unnecessary medical interventions across India.
1The Paradox of Overmedicalization
Modern medical capabilities have expanded rapidly, yet systemic overtreatment increasingly burdens patients across India. Prevention frequently devolves into cascading tests, permanent drug prescriptions, or unnecessary surgeries. Concurrently, Indian healthcare faces a sharp dichotomy: unneeded interventions are pushed onto insured segments while underprivileged populations still lack essential basic primary care access.
2Cascade of Unwarranted Testing
Excessive screening packages trigger clinical cascades, converting incidental abnormalities into overdiagnoses. A 2016 National Medical Journal of India review confirmed routine health packages frequently generate false positives and anxiety. Testing capacity has scaled much faster than clinical discretion regarding who actually requires investigations, prompting defensive medicine across crowded clinics.
3Fragmented Super-Specialist Care Models
Patients bypass primary practitioners to consult multiple super-specialists independently for common or chronic conditions. Each physician optimizes an isolated organ system without reconciling overall therapy. Consequently, human health is treated in disjointed fragments rather than holistically, severely undermining holistic care continuity and driving uncoordinated pharmacological regimens across urban centers.
4Alarming Rates of Polypharmacy
Data highlights severe overmedication among vulnerable demographics. A 2021 Frontiers in Pharmacology review documented polypharmacy in roughly 49% of older Indian adults. Furthermore, a 2025 Scientific Reports study found one-third taking five or more daily drugs, with 28.8% receiving inappropriate prescriptions, underscoring urgent deprescribing needs.
5Commercialization and Fee-for-Service Pressures
Healthcare commercialization transforms diagnostics, radiological scans, procedures, and supplements into aggressively marketed consumer products. Fee-for-service compensation models directly reward clinical volume rather than therapeutic restraint. In parallel, health insurance coverage generates moral hazards, incentivizing private hospitals and policyholders to pursue costlier invasive procedures over conservative clinical management.
6Defensive Medicine and Expectations
Patient expectations equate comprehensive care with tangible prescriptions, viewing lifestyle counseling as inadequate effort. Simultaneously, clinicians practice defensive medicine, ordering battery testing to eliminate rare diagnostic risks. This cycle ignores the inherent physical risks and financial costs linked directly to low-value diagnostic discoveries and unwarranted subsequent interventional pathways.
7Global Precedents for De-Implementation
Between 2012 and 2023, the global Choosing Wisely campaign published nearly 700 specialty recommendations to curb low-value clinical interventions. India must adopt similar standardized guidelines via the Indian Council of Medical Research, institutionalizing formal de-implementation into hospital accreditation, clinical training curricula, and quality evaluation programs across both sectors.
8Rebuilding Gatekeeping and Restraint
Reversing overtreatment requires empowering general physicians as the initial gatekeepers to oversee specialist referrals and medication reviews with mandatory stop dates. Insurers must pivot reimbursement toward holistic health outcomes instead of procedural volume. Future clinical progress hinges fundamentally on exercising disciplined medical restraint alongside advanced therapeutic innovation.